| 8.9 0.615 (7.42%) | 11-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.96  |
1-year : | 12.81 |
| Resists | First : | 9.39 |
Second : | 10.96 |
| Pivot price | 8.03  |
|||
| Supports | First : | 7.72 |
Second : | 6.69 |
| MAs | MA(5) : | 8.26 |
MA(20) : | 7.97 |
| MA(100) : | 7.25 |
MA(250) : | 4.48 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 67.5 |
D(3) : | 57.2 |
| RSI | RSI(14): 61 |
|||
| 52-week | High : | 9.69 | Low : | 1.02 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TNGX ] has closed Bollinger Bands are 20.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.08 - 9.12 | 9.12 - 9.15 |
| Low: | 8.41 - 8.45 | 8.45 - 8.49 |
| Close: | 8.83 - 8.9 | 8.9 - 8.96 |
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Wed, 19 Nov 2025
TNGX: Pivotal pancreatic cancer study advances, with strong combo data and cash runway into 2028 - TradingView
Tue, 18 Nov 2025
B. Riley Securities Maintains Tango Therapeutics (TNGX) Buy Recommendation - Nasdaq
Tue, 18 Nov 2025
Wolfe Research Initiates Coverage on Tango Therapeutics (TNGX) | - GuruFocus
Mon, 17 Nov 2025
Will Tango Therapeutics' (TNGX) Return to Profitability Shift Its Investment Narrative? - simplywall.st
Tue, 04 Nov 2025
Tango Therapeutics, Inc. (TNGX) Tops Q3 Earnings and Revenue Estimates - Nasdaq
Mon, 03 Nov 2025
Tango Therapeutics Inc (TNGX) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 135 (M) |
| Shares Float | 74 (M) |
| Held by Insiders | 4.9 (%) |
| Held by Institutions | 103.3 (%) |
| Shares Short | 29,390 (K) |
| Shares Short P.Month | 33,810 (K) |
| EPS | -0.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.42 |
| Profit Margin | -151.2 % |
| Operating Margin | 26.1 % |
| Return on Assets (ttm) | -24.6 % |
| Return on Equity (ttm) | -51.7 % |
| Qtrly Rev. Growth | 363.6 % |
| Gross Profit (p.s.) | -0.51 |
| Sales Per Share | 0.49 |
| EBITDA (p.s.) | -0.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -146 (M) |
| Levered Free Cash Flow | -62 (M) |
| PE Ratio | -9.79 |
| PEG Ratio | 0 |
| Price to Book value | 6.22 |
| Price to Sales | 18.01 |
| Price to Cash Flow | -8.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|